Clinical Trials Logo

Clinical Trial Summary

This is a Phase 1, non-randomized, sequential-cohort, dose escalation, open-label study designed to evaluate the safety and tolerability of RadProtect® in healthy volunteers. This study is to be conducted at two clinical centers and in conformity with Good Clinical Practice (GCP).


Clinical Trial Description

n/a


Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention


Related Conditions & MeSH terms


NCT number NCT02587442
Study type Interventional
Source Original BioMedicals Co. Ltd.
Contact Sandy Kan
Phone +886-2-2697-1713
Email sandykan@i-obm.com
Status Recruiting
Phase Phase 1
Start date October 2015

See also
  Status Clinical Trial Phase
Completed NCT00504335 - Safety and Pharmacokinetic Study of BIO 300 Capsules Phase 1
Completed NCT03585803 - A Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic/Pharmacodynamic Characteristics of KMRC011 Phase 1
Completed NCT04650555 - BIO 300 Oral Powder Safety and Pharmacokinetics Phase 1
Active, not recruiting NCT00903929 - Phase I Study of Eltrombopag for Promoting Thrombopoiesis After Total Body Irradiation Phase 1